Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. Its products portfolio includes Pantoprazole Sodium Enteric-coated, Ferrous Succinate, Rosuvastatin Calcium, Ebastine, and Rabeprazole Sodium Enteric-coated Tablets; and Acetylcysteine Granules, Potassium Sodium Hydrogen Citrate Granules, Loxoprofen Sodium Gel Pat… Read more
Hunan Jiudian Pharmaceutical Co Ltd (300705) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.02 Billion CNY
Based on the latest financial reports, Hunan Jiudian Pharmaceutical Co Ltd (300705) has total liabilities worth CN¥1.02 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hunan Jiudian Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Hunan Jiudian Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hunan Jiudian Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hunan Jiudian Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Shuangyi Technology Co Ltd
SHE:300690
|
China | CN¥361.46 Million |
|
SMA Solar Technology AG
PINK:SMTGF
|
USA | $987.75 Million |
|
Shanghai Huafon Aluminium Corp
SHG:601702
|
China | CN¥3.11 Billion |
|
Energy Recovery Inc
NASDAQ:ERII
|
USA | $28.81 Million |
|
Vallourec SA
PINK:VLOWY
|
USA | $2.56 Billion |
|
Tianshui Zhongxing Bio-technology Co Ltd
SHE:002772
|
China | CN¥3.16 Billion |
|
SK ETERNIX CO LT
KO:475150
|
Korea | ₩1.19 Trillion |
Liability Composition Analysis (2013–2024)
This chart breaks down Hunan Jiudian Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hunan Jiudian Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hunan Jiudian Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total liabilities of Hunan Jiudian Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥846.40 Million | -5.74% |
| 2023-12-31 | CN¥897.93 Million | +20.20% |
| 2022-12-31 | CN¥747.05 Million | +15.66% |
| 2021-12-31 | CN¥645.90 Million | +118.92% |
| 2020-12-31 | CN¥295.04 Million | -4.90% |
| 2019-12-31 | CN¥310.23 Million | +37.85% |
| 2018-12-31 | CN¥225.05 Million | +106.57% |
| 2017-12-31 | CN¥108.95 Million | +48.02% |
| 2016-12-31 | CN¥73.60 Million | +15.35% |
| 2015-12-31 | CN¥63.81 Million | +8.69% |
| 2014-12-31 | CN¥58.71 Million | -23.06% |
| 2013-12-31 | CN¥76.30 Million | -- |